Quarterly Report · 10-Q

Imunon, Inc.

IMNNNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 11, 2026Accepted Aug 11, 2026, 8:30 AM EDTCIK 749647Accession 0001493152-26-036991

Company context

Imunon is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms with the aim to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases.

Current securities

IMNNNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

Imunon, Inc. · 10-Q · Filed 2026-08-11

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common stock, par value $0.01 per share

Symbol: IMNN
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: From2026-01-01to2026-06-30

Dimensions: Not supplied

Accession 000149315226036991 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.